MajorClass III antiarrhythmic×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Dronedarone is a potent inhibitor of the transporter P-glycoprotein (P-gp) and a moderate inhibitor of the enzyme CYP3A4 (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Rivaroxaban is a substrate of both pathways, so dronedarone is likely to increase rivaroxaban exposure and the risk of bleeding (dronedarone SmPC, EMA). Clinical data on the pair are limited (rivaroxaban SmPC, EMA), and the European Heart Rhythm Association table rates the effect as moderate (EHRA 2021). For comparison, the strong inhibitors of both pathways ketoconazole and ritonavir increased the rivaroxaban area under the concentration–time curve (AUC) 2.6-fold and 2.5-fold (rivaroxaban SmPC, EMA). Dronedarone itself raises serum creatinine by 10 µmol/L on average, usually early in treatment, reaching a plateau by day 7 (dronedarone SmPC, EMA).
Symptoms
The main risk is bleeding (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). With long-term rivaroxaban, mucosal bleeding and anaemia were seen more often than with vitamin K antagonists. Examples are nosebleeds, gum bleeding, and gastrointestinal and genitourinary bleeding, including abnormal vaginal bleeding and heavier menstrual bleeding (rivaroxaban SmPC, EMA). An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (rivaroxaban SmPC, EMA).
Management
Avoid combining rivaroxaban with dronedarone because clinical data are limited (rivaroxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The dronedarone SmPC does not recommend the combination (dronedarone SmPC, EMA), and the European Heart Rhythm Association table says it should be avoided (EHRA 2021). The US label says rivaroxaban should not be used in patients with creatinine clearance of 15 to below 80 mL/min who take combined P-glycoprotein (P-gp) and moderate CYP3A inhibitors, unless the potential benefit justifies the potential risk (rivaroxaban label, US Food and Drug Administration, FDA). The US dronedarone label describes dronedarone as a moderate CYP3A inhibitor with the potential to inhibit P-gp (dronedarone label, FDA). Dronedarone is contraindicated when creatinine clearance is below 30 mL/min (dronedarone SmPC, EMA). Measure creatinine before starting dronedarone and after 7 days. If it has risen, measure it again after another 7 days. If there is no further rise, use this value as the new baseline (dronedarone SmPC, EMA). If rivaroxaban is nevertheless used with drugs that raise its levels in a patient with renal impairment, use it with caution (rivaroxaban SmPC, EMA). During dronedarone treatment, monitor co-administered anticoagulants (dronedarone SmPC, EMA). Stop rivaroxaban if severe bleeding occurs (rivaroxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- FDA: Xarelto (rivaroxaban) prescribing information (2026)– FDA label, DailyMed setid 10db92f9-2300-4a80-836b-673e1ae91610, version 65, revised 09/2026, sections 5.2 and 7
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5